These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27140801)

  • 1. Population pharmacokinetic analysis of thrombomodulin alfa to support dosing rationale in patients with renal impairment.
    Mouksassi MS; Marier JF; Bax L; Osawa Y; Tsuruta K
    Clin Pharmacol Drug Dev; 2015; 4(3):210-7. PubMed ID: 27140801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of recombinant human soluble thrombomodulin in disseminated intravascular coagulation patients with acute renal dysfunction.
    Hayakawa M; Kushimoto S; Watanabe E; Goto K; Suzuki Y; Kotani T; Kiguchi T; Yatabe T; Tagawa J; Komatsu F; Gando S
    Thromb Haemost; 2017 May; 117(5):851-859. PubMed ID: 28229162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects.
    Tsuruta K; Yamada Y; Serada M; Tanigawara Y
    J Clin Pharmacol; 2011 Sep; 51(9):1276-85. PubMed ID: 21098690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy.
    Asakura H; Takahashi H; Tsuji H; Matsushita T; Ninomiya H; Honda G; Mimuro J; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 Mar; 133(3):364-70. PubMed ID: 24440141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of thrombomodulin alfa in pediatric patients with hematological malignancy and disseminated intravascular coagulation.
    Takeuchi M; Tanoshima R; Miyagawa N; Sarashina T; Kato H; Kajiwara R; Ito S; Goto H
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27734584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.
    Saito H; Maruyama I; Shimazaki S; Yamamoto Y; Aikawa N; Ohno R; Hirayama A; Matsuda T; Asakura H; Nakashima M; Aoki N
    J Thromb Haemost; 2007 Jan; 5(1):31-41. PubMed ID: 17059423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis.
    Yamakawa K; Aihara M; Ogura H; Yuhara H; Hamasaki T; Shimazu T
    J Thromb Haemost; 2015 Apr; 13(4):508-19. PubMed ID: 25581687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of recombinant human soluble thrombomodulin in the management of HELLP syndrome complicated by DIC.
    Ikezoe T; Ikenoue N; Uchikawa N; Kojima S; Fukaya T; Yokoyama A
    Thromb Res; 2010 Sep; 126(3):e238-40. PubMed ID: 20627281
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment.
    Hayakawa M; Yamamoto H; Honma T; Mukai N; Higashiyama A; Sugano M; Kubota N; Uegaki S; Sawamura A; Gando S
    Shock; 2012 Jun; 37(6):569-73. PubMed ID: 22552020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan.
    Iba T; Thachil J
    Int J Hematol; 2016 Mar; 103(3):253-61. PubMed ID: 26588929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation.
    Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kuroda T; Sakata Y
    Thromb Res; 2013 May; 131(5):436-43. PubMed ID: 23566534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
    Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
    BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic and Adverse Effects of Thrombomodulin Alfa to Treat Sepsis-Induced Disseminated Intravascular Coagulation.
    Imaura M; Tsumori M; Nagase S; Omura K; Takahashi H; Hatoyama-Tanaka S; Katagiri F; Takayanagi R; Kanno H; Yamada Y
    Shock; 2020 Jul; 54(1):50-55. PubMed ID: 31764622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.
    Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I
    Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
    Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
    J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin.
    Hoppensteadt D; Tsuruta K; Cunanan J; Hirman J; Kaul I; Osawa Y; Fareed J
    Clin Appl Thromb Hemost; 2014 Mar; 20(2):129-35. PubMed ID: 23804232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study.
    Akahoshi T; Sugimori H; Kaku N; Tokuda K; Nagata T; Noda E; Morita M; Hashizume M; Maehara Y
    Eur J Trauma Emerg Surg; 2015 Oct; 41(5):531-8. PubMed ID: 26038004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.
    Papageorgiou C; Jourdi G; Adjambri E; Walborn A; Patel P; Fareed J; Elalamy I; Hoppensteadt D; Gerotziafas GT
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):8S-28S. PubMed ID: 30296833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
    Macias WL; Dhainaut JF; Yan SC; Helterbrand JD; Seger M; Johnson G; Small DS
    Clin Pharmacol Ther; 2002 Oct; 72(4):391-402. PubMed ID: 12386641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation.
    Murao A; Kato T; Yamane T; Honda G; Eguchi Y
    Clin Appl Thromb Hemost; 2022; 28():10760296221077096. PubMed ID: 35166576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.